middle.news

INOVIQ Defends Lab Study Claim of 88% Cancer Cell Kill Rate

6:01pm on Monday 23rd of June, 2025 AEST Healthcare
Read Story

INOVIQ Defends Lab Study Claim of 88% Cancer Cell Kill Rate

6:01pm on Monday 23rd of June, 2025 AEST
Key Points
  • INOVIQ confirms 88% cancer cell death in lab-based in vitro studies
  • Study conducted in-house with ongoing validation at Peter MacCallum Cancer Institute
  • Company justifies use of 'treatment' and forward-looking statements despite early research stage
  • Detailed statistical analysis supports significance of results
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Inoviq (ASX:IIQ)
OPEN ARTICLE